Comparison of Depression Interventions After Acute Coronary Syndrome (CODIACS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01032018|
Recruitment Status : Completed
First Posted : December 15, 2009
Results First Posted : August 12, 2014
Last Update Posted : September 13, 2017
Patients will be consented and screened within 2 to 6 months of the index ACS. Patients who have elevated depression (BDI>=15 or BDI>=10 assessed twice over two week period) and who continue to meet all of the trial's eligibility criteria will be consented. Through informed consent, both arms of the trial will be described with equipoise as to these approaches to postACS depression care. Patients who consent to randomization will be enrolled in the treatment trial.
The intervention phase will be 6 months, and hence the final outcome assessments will be performed approximately 9 months after the index ACS. Interim measures of depression will be obtained at 2 and 4 months post-enrollment. Major adverse cardiac events and all-cause mortality will also be ascertained at 6 months post-enrollment. Quality assurance by an independent medical event adjudication committee using prospective guidelines will be employed.
|Condition or disease||Intervention/treatment||Phase|
|Acute Coronary Syndrome Depression||Behavioral: Problem Solving Therapy Drug: Sertraline, citalopram, or bupropion Other: Standard care||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||150 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||Comparison of Depression Interventions After Acute Coronary Syndrome (CODIACS)|
|Study Start Date :||January 2010|
|Actual Primary Completion Date :||January 2012|
|Actual Study Completion Date :||July 2012|
Active Comparator: Referred Care
Immediately after the initial post-ACS screening, the participant's physician will be notified in writing if the participant is depressed according to the BDI. Depending upon the physician's own evaluation of the participant, he or she may elect to defer depression treatment, initiate it, or to refer the patient to a mental health specialist.
Other: Standard care
Participants will receive standard of care from the current physicians
Experimental: Stepped Care
Stepped Care participants will be given a description of the choices available in this arm, including choosing antidepressant medication and/or telephone-based, Problem-Solving Therapy (PST). If the patient is randomized to Stepped Care, their physician will be informed that depression treatment is being provided by the trial. Patients will select their preferred treatment approach. Depression symptoms will be monitored to determine whether the patient is improving relative to his/her baseline score. Relapse monitoring and maintenance therapy will continue for the duration of the study.
Behavioral: Problem Solving Therapy
Problem Solving Therapy (PST) will be administered by a trained provider. The concepts of PST will be taught to the participant in the first session and reinforced across subsequent sessions. Sessions will last between 30 and 60 minutes each and continue weekly for the duration of the study (6 months).
Drug: Sertraline, citalopram, or bupropion
Antidepressants should be started at the lowest dose, but should be adjusted upward to be within the therapeutic range within 1 week,with further adjustment higher in the therapeutic range possible at 3-4 weeks. Dosage of the first medication selected will be in the therapeutic range by 3 weeks of the initial step, as tolerated. If a patient cannot tolerate a particular treatment (i.e., intolerable side effects even with careful titration and clinical management), a switch to an alternative antidepressant or PST-PC after 2-4 weeks and 'restart' step 1.
Sertraline: 25-150qam Citalopram: 10-40qam Bupropion: 100-450qam
- Depressive Symptom Reduction [ Time Frame: Change from depression at baseline to depression at 6-months ]Symptoms of depression were assessed using the Beck Depression Inventory (BDI). This 21-question, multiple choice self-report instrument includes items pertaining to symptoms of depression, including hopelessness and irritability, physical symptoms such as fatigue, and thoughts such as guilt. Each item has at a set of four possible responses, ranging in intensity for least intense to most intense. The total score is calculated by adding the responses to each item. Higher scores indicate more severe depressive symptoms. The total score on the scale ranges from 0 to 63. Total scores on the scale of less 10 indicate minimal depression; total scores between 10 and 15 indicate mild depression; and total scores greater than 16 indicate a probable clinical diagnosis of depression.
- Cost for Healthcare Utilization (Psychiatric Medications, Hospitalizations, Cardiac Procedures, Outpatient Services) [ Time Frame: 6 months after randomization ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01032018
|United States, Connecticut|
|New Haven, Connecticut, United States, 06520|
|United States, Georgia|
|Atlanta, Georgia, United States, 30322|
|United States, Missouri|
|Saint Louis, Missouri, United States, 63130|
|United States, New York|
|Columbia University Medical Center|
|New York, New York, United States, 10032|
|United States, Pennsylvania|
|Trustees of the University of Pennsylvania, Penn Cardiac Center at Mercer Bucks|
|Yardley, Pennsylvania, United States, 19067|
|Principal Investigator:||Karina W Davidson, PhD||Columbia University|
|Principal Investigator:||J Thomas Bigger, MD||Columbia University|
|Principal Investigator:||Robert Carney, PhD||Washington University School of Medicine|
|Principal Investigator:||Kenneth Freedland, PhD||Washington University School of Medicine|